72693-56-2

Upstream product

• 52-89-1 l-cysteine hydrochloride 
• 552-89-6 2-nitro-benzaldehyde 

Downstream Products

• 72678-67-2 (R)-3-((S)-3-Benzoylsulfanyl-2-methyl-propionyl)-2-(2-nitro-phenyl)-thiazolidine-4-carboxylic acid 
• 72679-35-7 (R)-3-((S)-3-Mercapto-2-methyl-propionyl)-2-(2-nitro-phenyl)-thiazolidine-4-carboxylic acid 
• 1297309-29-5 3-(2-chloro-acetyl)-(2RS,4R)-2-(2-nitro-phenyl)-thiazolidine-4-carboxylic acid 
• 1297309-36-4 3-phenylacetyl-(2RS,4R)-2-(2-nitro-phenyl)-thiazolidine-4-carboxylic acid 

Relevant academic research and scientific papers

X-ray crystal structures and anti-breast cancer property of 3-tert -butoxycarbonyl-2-arylthiazolidine-4-carboxylic acids

Diastereomeric '2RS,4R'-2-arylthiazolidine-4-carboxylic acids (ATCAs) were synthesized and their resolution to chiraly pure N-BOC derivatives was attempted by column chromatography. The absolute stereochemistry of the resolved compounds was ascertained by X-ray single crystal structures. Further application of the synthesized compounds was studied for their in vitro anti-breast cancer activity against MCF7 cell line using DOX as a standard by MTT assay method. Cell morphology analysis was carried out by fluorescence microscopy. The compounds containing '2S' absolute configuration in thiazolidine ring and presence of 2-NO2, 2,6-Cl groups on '2R'-aryl substituent showed significant anti-breast cancer activity where some of the compounds were found to be more active than DOX in terms of induced apoptosis mode of MCF7 cell death.

Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors

A series of thiazolidine-4-carboxylic acid derivatives were synthesized and evaluated for their ability to inhibit neuraminidase (NA) of influenza A virus. All the compounds were synthesized in good yields starting from commercially available l-cysteine hydrochloride using a suitable synthetic strategy. These compounds showed moderate inhibitory activity against influenza A neuraminidase. The most potent compound of this series is compound 4f (IC50 = 0.14 μM), which is about sevenfold less potent than oseltamivir and could be used to design novel influenza NA inhibitors that exhibit increased activity based on thiazolidine ring.